209 related articles for article (PubMed ID: 21861932)
21. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Miettinen S; Ylikomi T
Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654
[TBL] [Abstract][Full Text] [Related]
22. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
Gregory-Bass RC; Olatinwo M; Xu W; Matthews R; Stiles JK; Thomas K; Liu D; Tsang B; Thompson WE
Int J Cancer; 2008 May; 122(9):1923-30. PubMed ID: 18183577
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
24. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
Narendrula R; Mispel-Beyer K; Guo B; Parissenti AM; Pritzker LB; Pritzker K; Masilamani T; Wang X; Lannér C
BMC Cancer; 2016 Feb; 16():146. PubMed ID: 26911141
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N
Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451
[TBL] [Abstract][Full Text] [Related]
26. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
27. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.
Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR
Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors.
Fu W; Lan H; Li S; Han X; Gao T; Ren D
Cancer Gene Ther; 2008 Jul; 15(7):474-84. PubMed ID: 18437183
[TBL] [Abstract][Full Text] [Related]
31. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.
Bharara S; Sorscher EJ; Gillespie GY; Lindsey JR; Hong JS; Curlee KV; Allan PW; Gadi VK; Alexander SA; Secrist JA; Parker WB; Waud WR
Hum Gene Ther; 2005 Mar; 16(3):339-47. PubMed ID: 15812229
[TBL] [Abstract][Full Text] [Related]
33. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
35. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.
Parker WB; King SA; Allan PW; Bennett LL; Secrist JA; Montgomery JA; Gilbert KS; Waud WR; Wells AH; Gillespie GY; Sorscher EJ
Hum Gene Ther; 1997 Sep; 8(14):1637-44. PubMed ID: 9322865
[TBL] [Abstract][Full Text] [Related]
36. Suicide gene/prodrug therapy using salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2'-deoxyriboside in murine mammary carcinoma 4T1 model.
Fu W; Lan H; Liang S; Gao T; Ren D
Cancer Sci; 2008 Jun; 99(6):1172-9. PubMed ID: 18429958
[TBL] [Abstract][Full Text] [Related]
37. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.
Mohr L; Shankara S; Yoon SK; Krohne TU; Geissler M; Roberts B; Blum HE; Wands JR
Hepatology; 2000 Mar; 31(3):606-14. PubMed ID: 10706550
[TBL] [Abstract][Full Text] [Related]
39. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.
Xie X; Guo J; Kong Y; Xie GX; Li L; Lv N; Xiao X; Tang J; Wang X; Liu P; Yang M; Xie Z; Wei W; Spencer DM; Xie X
J Gene Med; 2011 Dec; 13(12):680-91. PubMed ID: 22009763
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]